RxDoctor Payments Data

James Coman, MD

Clinical Cardiac Electrophysiology · Tulsa, OKNPI 1417927815

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,350 of the $23,998 with a category attached, or 93.1%. Boston Scientific accounts for 94.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $9,173 and has fallen 97.9% since, to $188 in 2025.

$23,998in general payments, 2019–2025

Across 76 payments — averaging $315.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$23K
  • Medtronic$282
  • E.r. Squibb & Sons, L.L.C.$231
  • Impulse Dynamics (USA) Inc.$188
  • Abbott$174
  • Kestra Medical Technology Services, Inc.$136
  • plus $411 from 8 others

What the payments were for

  • Consulting fees$22,35093%
  • Food & beverage$1,6487%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,998 in reported general payments places this provider in the 60th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

See all clinical cardiac electrophysiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$349,310
Medicare patients
731
Services billed
3,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban383$339,247
XareltoRivaroxaban197$163,525
Metoprolol Succinate244$4,298
Dabigatran EtexilateDabigatran Etexilate Mesylate15$3,369
Nadolol23$1,619
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,215
Amiodarone Hcl120$1,188
SotalolSotalol Hcl50$1,079
Flecainide Acetate33$717
Verapamil ErVerapamil Hcl14$324
Metoprolol Tartrate27$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$80$339,247383 claims
Johnson & JohnsonXarelto$89$163,525197 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

Other clinical cardiac electrophysiology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →